Literature DB >> 15366647

Nail changes during docetaxel containing combination chemotherapy.

In Sook Woo1, Kon Ho Shim, Gi Young Kim, Myung Ah Lee, Jin Hyoung Kang, Young Seon Hong, Kyung Shik Lee.   

Abstract

Nail toxicity following systemic chemotherapy is common. Onychopathy during the period of neutropenia following chemotherapy may cause subungual abscesses and serious infection. Despite taxoid-related toxicity being increasingly reported since 2000, there are still phase II systemic chemotherapy studies using taxoid that have never mentioned nail changes. Recently, new criteria for the evaluation of nail toxicity have been suggested. The present report is the first of its kind, in Korea, to describe a case of docetaxel-associated onychopathy, which improved following a reduction in the docetaxel dose.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15366647      PMCID: PMC4531594          DOI: 10.3904/kjim.2004.19.2.132

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  9 in total

1.  Clinical picture: nail changes secondary to docetaxel.

Authors:  G Wasner; F Hilpert; R Baron; J Pfisterer
Journal:  Lancet       Date:  2001-03-24       Impact factor: 79.321

2.  Nail toxicity related to weekly taxanes: an important issue requiring a change in common toxicity criteria grading?

Authors:  Simon Spazzapan; Diana Crivellari; Davide Lombardi; Cristina Scuderi; Maria Donatella Magri; Andrea Veronesi; Alessandro Gatti
Journal:  J Clin Oncol       Date:  2002-11-01       Impact factor: 44.544

Review 3.  Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature.

Authors:  S Hussain; D N Anderson; M E Salvatti; B Adamson; M McManus; A S Braverman
Journal:  Cancer       Date:  2000-05-15       Impact factor: 6.860

Review 4.  Cutaneous photosensitivity diseases induced by exogenous agents.

Authors:  J W Gould; M G Mercurio; C A Elmets
Journal:  J Am Acad Dermatol       Date:  1995-10       Impact factor: 11.527

5.  Docetaxel administered on a weekly basis for metastatic breast cancer.

Authors:  H J Burstein; J Manola; J Younger; L M Parker; C A Bunnell; R Scheib; U A Matulonis; J E Garber; K D Clarke; L N Shulman; E P Winer
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

6.  Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.

Authors:  J D Hainsworth; H A Burris; D A Yardley; J E Bradof; M Grimaldi; L A Kalman; T Sullivan; M Baker; J B Erland; F A Greco
Journal:  J Clin Oncol       Date:  2001-08-01       Impact factor: 44.544

7.  Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer.

Authors:  E A Perez; C L Vogel; D H Irwin; J J Kirshner; R Patel
Journal:  J Clin Oncol       Date:  2001-11-15       Impact factor: 44.544

8.  Docetaxel-induced nail changes--a neurogenic mechanism: a case report.

Authors:  Gunnar Wasner; Felix Hilpert; Jörn Schattschneider; Andreas Binder; Jacobus Pfisterer; Ralf Baron
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

9.  Taxane-induced nail changes: incidence, clinical presentation and outcome.

Authors:  A M Minisini; A Tosti; A F Sobrero; M Mansutti; B M Piraccini; C Sacco; F Puglisi
Journal:  Ann Oncol       Date:  2003-02       Impact factor: 32.976

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.